Quercitrin and taxifolin stimulate osteoblast differentiation in MC3T3-E1 cells and inhibit osteoclastogenesis in RAW 264.7 cells.
Flavonoids are natural antioxidants that positively influence bone metabolism. The present study screened among different flavonoids to identify biomolecules for potential use in bone regeneration. For this purpose, we used MC3T3-E1 and RAW264.7 cells to evaluate their effect on cell viability and cell differentiation. First, different doses of chrysin, diosmetin, galangin, quercitrin and taxifolin were analyzed to determine the optimum concentration to induce osteoblast differentiation. After 48h of treatment, doses ≥100μM of diosmetin and galangin and also 500μM taxifolin revealed a toxic effect on cells. The same effect was observed in cells treated with doses ≥100μM of chrysin after 14 days of treatment. However, the safe doses of quercitrin (200 and 500μM) and taxifolin (100 and 200μM) induced bone sialoprotein and osteocalcin mRNA expression. Also higher osteocalcin secreted levels were determined in 100μM taxifolin osteoblast treated samples when compared with the control ones. On the other hand, quercitrin and taxifolin decreased Rankl gene expression in osteoblasts, suggesting an inhibition of osteoclast formation. Indeed, osteoclastogenesis suppression by quercitrin and taxifolin treatment was observed in RAW264.7 cells. Based on these findings, the present study demonstrates that quercitrin and taxifolin promote osteoblast differentiation in MC3T3-E1 cells and also inhibit osteoclastogenesis in RAW264.7 cells, showing a positive effect of these flavonoids on bone metabolism.
Group of Cell Therapy and Tissue Engineering, Research Institute on Health Sciences (IUNICS), University of Balearic Islands, Palma de Mallorca, Spain.
María
M
Satué
Maria del Mar
Mdel M
Arriero
Marta
M
Monjo
Joana Maria
JM
Ramis
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D058574:Integrin-Binding Sialoprotein / Q000235:genetics / Q000378:metabolism; D008264:Macrophages / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D010012:Osteogenesis; D011794:Quercetin / Q000031:analogs & derivatives* / Q000494:pharmacology
D015415:Biomarkers; D005419:Flavonoids; C546872:Ibsp protein, mouse; D058574:Integrin-Binding Sialoprotein; D015675:Osteocalcin; C037032:galangin; C012526:quercitrin; C043561:chrysin; D011794:Quercetin; C003377:taxifolin; C039602:diosmetin
18S rRNA; 18S ribosomal RNA; A disintegrin and metalloproteinase domain-containing protein 8 (Adam8) and Dendritic cell-specific transmembrane protein; Bsp; CtsK; DMSO; Dc-Stamp; Flavonoid; Gapdh; H(+)-ATPase; Integrin alpha-V; Itgav; Itgb3; Mmp-9; Oc; Opg; Osteoblast; Osteoclast; Quercitrin; Rank; Rankl; Taxifolin; Trap; bone sialoprotein; cathepsin K; dimethyl sulfoxide; glyceraldehyde-3-phosphate dehydrogenase; integrin beta-3; metalloproteinase-9; osteocalcin; osteoprogeterin; receptor activator of nuclear factor kappa-B; receptor activator of nuclear factor kappa-B ligand; tartrate resistant acid phosphatase; vacuolar-type H(+) ATPase